logo
Sign in

Keith Wycoff

Principal investigator.

Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$18.1MFederal grants as PI34 awards
0Patents grantedNone matched
0PapersOpenAlex
Career record

Federal awards and patents by year

20152025
AwardsPatents
Federal awards as principal investigator

34 awards · $18.1M

DateAgencyAwardAmountCompany
Aug 5, 2025NIHSBIR Phase I
Bispecific antibody for topical administration to prevent gonorrhea
$300KPlanet Biotechnology Incorporated
Jul 23, 2025NIHSBIR Phase I
Factor H-Fc Fusion as a Pre-Exposure Prophylactic for Rickettsia Infections
$295KPlanet Biotechnology Incorporated
Jul 15, 2025NIHSTTR Phase I
Developing a Potent Broad-Spectrum Prophylactic for Tickborne Disease
$300KPlanet Biotechnology Incorporated
May 1, 2025NIHSTTR Phase I
A broad spectrum anti-gonorrhea immunotherapeutic
$297KPlanet Biotechnology Incorporated
Jul 30, 2024NIHSBIR Phase I
Bispecific antibody for topical administration to prevent gonorrhea
$300KPlanet Biotechnology Incorporated
Jul 29, 2024NIHSTTR Phase I
Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections
$300KPlanet Biotechnology Incorporated
Jul 17, 2024NIHSTTR Phase I
Developing a Potent Broad-Spectrum Prophylactic for Tickborne Disease
$300KPlanet Biotechnology Incorporated
Jul 10, 2024NIHSBIR Phase I
Factor H-Fc Fusion as a Pre-Exposure Prophylactic for Rickettsia Infections
$300KPlanet Biotechnology Incorporated
Apr 4, 2024NIHSTTR Phase I
A broad spectrum anti-gonorrhea immunotherapeutic
$300KPlanet Biotechnology Incorporated
Aug 10, 2023NIHSTTR Phase I
Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections
$300KPlanet Biotechnology Incorporated
Aug 10, 2023NIHSTTR Phase I
Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections
$300KPlanet Biotechnology Incorporated
with UNIVERSITY OF TOLEDO
May 11, 2023NIHSBIR Phase II
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
$1.0MPlanet Biotechnology Incorporated
May 16, 2022NIHSBIR Phase II
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
$1.0MPlanet Biotechnology Incorporated
May 16, 2022NIHSBIR Phase II
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
$2.0MPlanet Biotechnology Incorporated
Jun 25, 2021NIHSTTR Phase I
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
$182KPlanet Biotechnology Incorporated
Apr 21, 2021NIHSBIR Phase II
An immunotherapeutic to prevent gonorrhea
$929KPlanet Biotechnology Incorporated
Jul 17, 2020NIHSTTR Phase I
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
$263KPlanet Biotechnology Incorporated
Jul 17, 2020NIHSTTR Phase I
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
$445KPlanet Biotechnology Incorporated
with UNIVERSITY OF NORTH DAKOTA
Apr 1, 2020NIHSTTR Phase I
Recombinant Fc fusions for treatment of uropathogenic E. coli
$487KPlanet Biotechnology Incorporated
with UNIVERSITY OF WASHINGTON
Mar 31, 2020NIHSTTR Phase I
Recombinant Fc fusions for treatment of uropathogenic E. coli
$487KPlanet Biotechnology Incorporated
Mar 11, 2020NIHSBIR Phase II
An immunotherapeutic to prevent gonorrhea
$1.7MPlanet Biotechnology Incorporated
Mar 11, 2020NIHSBIR Phase II
An immunotherapeutic to prevent gonorrhea
$798KPlanet Biotechnology Incorporated
Mar 1, 2020NIHSBIR Phase I
Improving gene expression via Massively Parallel Synonymous Codon Variant Screening
$299KPlanet Biotechnology Incorporated
Feb 21, 2020NIHSBIR Phase I
Improving gene expression via Massively Parallel Synonymous Codon Variant Screening
$299KPlanet Biotechnology Incorporated
Jul 22, 2019NIHSBIR Phase II
An immunotherapeutic to prevent gonorrhea
$300KPlanet Biotechnology Incorporated
Jul 4, 2018NIHSBIR Phase I
An immunoadhesin therapy for glioblastoma targeting CD97
$264KPlanet Biotechnology Incorporated
Jul 4, 2018NIHSBIR Phase I
An immunoadhesin therapy for glioblastoma targeting CD97
$264KPlanet Biotechnology Incorporated
Feb 22, 2017NIHSBIR Phase I
A mucosally targeted MERS-CoV vaccine produced in plants
$236KPlanet Biotechnology Incorporated
Feb 17, 2017NIHSBIR Phase I
A mucosally targeted MERS CoV vaccine produced in plants
$236KPlanet Biotechnology Incorporated
Feb 13, 2017NIHSTTR Phase I
A novel anti gonorrhea immunotherapeutic
$242KPlanet Biotechnology Incorporated
with UNIV OF MASSACHUSETTS MED SCH WORCESTER
Feb 13, 2017NIHSTTR Phase I
A novel anti-gonorrhea immunotherapeutic
$242KPlanet Biotechnology Incorporated
Jul 27, 2016NIHSBIR Phase II
A MERS-CoV Receptor Decoy
$773KPlanet Biotechnology Incorporated
Aug 14, 2015NIHSBIR Phase II
A MERS-CoV Receptor Decoy
$802KPlanet Biotechnology Incorporated
Aug 14, 2015NIHSBIR Phase II
A MERS-CoV Receptor Decoy
$1.6MPlanet Biotechnology Incorporated
Among 4,078 researchers in Biotech

Peer ranks

Federal funding#10
Awards as PI#3
Patents#273
From filings, awards and patents

Companies

Research partners on awards

Research institutions

Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.